Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis
Impaired kidney function may influence pharmacokinetics of most of the drugs, including the ones used in COVID-19. In this publication, the most important pharmacokinetic parameters and dose adjustment approaches are provided, based on The Renal Drug Handbook и Sanford Guide. In the majority of case...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
Izdatelstvo OKI
2020-10-01
|
Series: | Качественная клиническая практика |
Subjects: | |
Online Access: | https://www.clinvest.ru/jour/article/view/524 |
_version_ | 1797262078077042688 |
---|---|
author | V. M. Tsvetov I. N. Sychev D. A. Sychev |
author_facet | V. M. Tsvetov I. N. Sychev D. A. Sychev |
author_sort | V. M. Tsvetov |
collection | DOAJ |
description | Impaired kidney function may influence pharmacokinetics of most of the drugs, including the ones used in COVID-19. In this publication, the most important pharmacokinetic parameters and dose adjustment approaches are provided, based on The Renal Drug Handbook и Sanford Guide. In the majority of cases, mild kidney function reduction does not necessitate dose adjustment. Each case should be considered individually, measuring benefits against risks. |
first_indexed | 2024-04-24T23:51:23Z |
format | Article |
id | doaj.art-eefaef53ceca4ec982953d6774cca397 |
institution | Directory Open Access Journal |
issn | 2588-0519 2618-8473 |
language | Russian |
last_indexed | 2024-04-24T23:51:23Z |
publishDate | 2020-10-01 |
publisher | Izdatelstvo OKI |
record_format | Article |
series | Качественная клиническая практика |
spelling | doaj.art-eefaef53ceca4ec982953d6774cca3972024-03-14T18:09:08ZrusIzdatelstvo OKIКачественная клиническая практика2588-05192618-84732020-10-0104S394610.37489/2588-0519-2020-S4-39-46508Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysisV. M. Tsvetov0I. N. Sychev1D. A. Sychev2ФГБУ «Федеральный центр сердечно-сосудистой хирургии» Минздрава РоссииФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; ГБУЗ ГКБ им. С.С. Юдина ДЗМФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииImpaired kidney function may influence pharmacokinetics of most of the drugs, including the ones used in COVID-19. In this publication, the most important pharmacokinetic parameters and dose adjustment approaches are provided, based on The Renal Drug Handbook и Sanford Guide. In the majority of cases, mild kidney function reduction does not necessitate dose adjustment. Each case should be considered individually, measuring benefits against risks.https://www.clinvest.ru/jour/article/view/524коронавирусхроническая почечная недостаточностьдиализcovid-19 |
spellingShingle | V. M. Tsvetov I. N. Sychev D. A. Sychev Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis Качественная клиническая практика коронавирус хроническая почечная недостаточность диализ covid-19 |
title | Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis |
title_full | Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis |
title_fullStr | Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis |
title_full_unstemmed | Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis |
title_short | Use of etiotropic and pathogenetic medicines for COVID-19 in patients with renal failure and/or on dialysis |
title_sort | use of etiotropic and pathogenetic medicines for covid 19 in patients with renal failure and or on dialysis |
topic | коронавирус хроническая почечная недостаточность диализ covid-19 |
url | https://www.clinvest.ru/jour/article/view/524 |
work_keys_str_mv | AT vmtsvetov useofetiotropicandpathogeneticmedicinesforcovid19inpatientswithrenalfailureandorondialysis AT insychev useofetiotropicandpathogeneticmedicinesforcovid19inpatientswithrenalfailureandorondialysis AT dasychev useofetiotropicandpathogeneticmedicinesforcovid19inpatientswithrenalfailureandorondialysis |